Stephens Inc. AR Makes New Investment in Blueprint Medicines Co. (NASDAQ:BPMC)

Stephens Inc. AR purchased a new position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 3,684 shares of the biotechnology company's stock, valued at approximately $321,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Pallas Capital Advisors LLC grew its holdings in shares of Blueprint Medicines by 3.2% in the third quarter. Pallas Capital Advisors LLC now owns 5,657 shares of the biotechnology company's stock worth $523,000 after purchasing an additional 176 shares during the last quarter. Franklin Resources Inc. boosted its position in Blueprint Medicines by 0.7% in the 3rd quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company's stock valued at $3,259,000 after buying an additional 265 shares during the period. Quarry LP bought a new position in Blueprint Medicines in the 3rd quarter worth about $32,000. Covestor Ltd increased its position in shares of Blueprint Medicines by 206.7% during the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company's stock worth $55,000 after acquiring an additional 403 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Blueprint Medicines by 22.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,291 shares of the biotechnology company's stock valued at $212,000 after acquiring an additional 422 shares in the last quarter.

Wall Street Analysts Forecast Growth

BPMC has been the subject of a number of research reports. UBS Group began coverage on shares of Blueprint Medicines in a research note on Thursday, October 24th. They issued a "neutral" rating and a $88.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and set a $135.00 target price on shares of Blueprint Medicines in a research report on Friday, February 14th. Piper Sandler lifted their price objective on shares of Blueprint Medicines from $109.00 to $119.00 and gave the stock a "neutral" rating in a research note on Monday, January 27th. Needham & Company LLC reiterated a "buy" rating and set a $133.00 price target on shares of Blueprint Medicines in a research note on Thursday, February 13th. Finally, JPMorgan Chase & Co. increased their price objective on Blueprint Medicines from $126.00 to $129.00 and gave the company an "overweight" rating in a report on Tuesday, February 4th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Blueprint Medicines currently has an average rating of "Moderate Buy" and an average price target of $123.83.

Blueprint Medicines Price Performance

Shares of NASDAQ:BPMC traded up $1.54 during trading on Wednesday, reaching $94.02. 608,216 shares of the company's stock traded hands, compared to its average volume of 1,033,168. The firm has a market cap of $6.01 billion, a PE ratio of -87.06 and a beta of 0.62. Blueprint Medicines Co. has a fifty-two week low of $80.42 and a fifty-two week high of $121.90. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. The company has a 50-day simple moving average of $99.54 and a 200-day simple moving average of $94.40.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. As a group, analysts predict that Blueprint Medicines Co. will post -1.22 earnings per share for the current year.

Insider Buying and Selling

In other Blueprint Medicines news, insider Ariel Hurley sold 1,819 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $93.26, for a total transaction of $169,639.94. Following the completion of the transaction, the insider now owns 14,967 shares of the company's stock, valued at $1,395,822.42. This represents a 10.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jeffrey W. Albers sold 15,000 shares of Blueprint Medicines stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $89.77, for a total value of $1,346,550.00. Following the completion of the sale, the director now directly owns 157,557 shares in the company, valued at $14,143,891.89. This represents a 8.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 49,851 shares of company stock valued at $4,984,696. 4.21% of the stock is owned by corporate insiders.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.